6505--Radiopharmaceuticals RMR VAMC 5-year IDIQ
Awarded on January 29, 2026. Full description on SAM.gov.
Overview
- Posted
- January 29, 2026
- Notice type
- Award Notice
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of Veterans Affairs
Notice details
- Office
- NETWORK CONTRACT OFFICE 19 (36C259)
- Place of performance
- Department of Veterans Affairs Rocky Mountain Regional VAMC, Aurora, CO, 80045
- Last updated
- Nov 3, 2026
- First published
- Last updated on SAM.gov
- Award date
- Jan 29, 2026
- Award amount (SAM.gov award notice)
- $0
Identifiers
- Solicitation number
- 36C25926Q0144
- Notice ID
- 03dd4ad0ceec495aaa3d1563e0072a23
- Award number (PIID)
- 36C25926D0018
Description
Award Overview
Award Number
36C25926D0018
Award Amount (SAM.gov award notice)
$0
Award Date
Jan 29, 2026
Awardee
Awardee UEI
CWN9UGL3NCL9
Awardee CAGE Code
3S229
Awardee Address
DUBLIN, OH 43017, OH
Line Item Number
240
Original Solicitation
Notice ID: 03dd4ad0ceec495aaa3d1563e0072a23
Posted Date: Jan 29, 2026
Original Response Deadline: Not specified
Task Orders Under This IDV
Top 10 by total obligated
- $511.5KSigned Jan 30, 2026
- $511.5KSigned Feb 26, 2026
More From This Vendor
Top 5 most recent
- $387.3KSigned Nov 5, 2026
- $1.7MSigned Nov 4, 2026
- $68.9KSigned Nov 4, 2026
- $89.5KSigned Nov 4, 2026
- $604.1KSigned Nov 3, 2026
Contacts
Contracting Officer
Primary Contact
Documents
Files (7)
- Download
36C25926Q0144 0001.docx
15 KBAdded in Combined Synopsis/Solicitation version 6Posted - Download
Attachment 3 - Authorized Caller List.docx
15 KBAdded in Combined Synopsis/Solicitation version 1Posted - Download
Attachment 2 - FAR 52.225-2 Buy American Certificate.docx
14 KBAdded in Combined Synopsis/Solicitation version 1Posted - Download
Attachment 1 - Radiopharmaceutical Items.xlsx
23 KBAdded in Combined Synopsis/Solicitation version 1Posted - Download
SOW Radiopharmaceuticals.docx
71 KBAdded in Combined Synopsis/Solicitation version 1Posted - Download
36C25926D0018_1.docx
13 KBAdded in Award Notice version 4Posted - Download
36C25926Q0144.docx
39 KBAdded in Combined Synopsis/Solicitation version 1Posted
Lifecycle
- 5Version 5Combined Synopsis/SolicitationArchived
6505--Radiopharmaceuticals RMR VAMC 5-year IDIQ
- 4Version 4Award NoticeArchivedCurrent
Type changed from Combined Synopsis/Solicitation to Award Notice
6505--Radiopharmaceuticals RMR VAMC 5-year IDIQ
Other notices for this solicitation
- Combined SynopsisRelated noticeJan 8, 2026
6505--Radiopharmaceuticals RMR VAMC 5-year IDIQ
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Sources Sought Notice - General Radioisotopes (Diagnostic & Therapeutic) Disclaimer: This Request for Information (RFI) is issued solely for market research information and planning purposes and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. Responses to this notice are NOT offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. Information Requested from Industry: In response to the Sources Sought, interested Contractors shall submit the following information and any Capabilities/Qualifications Statement to include but not limited to an overview of proposed solution(s) and a description of the product your company possesses in accordance with the draft Statement of Work (SOW) / general requirement and deliverables list. Responses to market research questions shall be submitted. If this information is not provided, then it will be assumed the entire requirement cannot be met. Confirmation that interested party can meet the required timelines listed in draft SOW. Description of Requirement: The Department of Veterans Affairs, Veterans Health Administration (VHA), Network Contracting Office 19 (NCO 19) is conducting a market survey and is seeking potential sources for unit dose radiopharmaceuticals, radioactive sources, and supplies for diagnostic imaging exams and quality assurance procedures (brand name or equal) for the Salt Lake City VA Medical Center. This Sources Sought Notice is issued for information and planning purposes only. This is not a solicitation or a request for proposal and shall not be construed as an obligation or commitment by the Government. An award will not be made on any offers submitted in response to this notice, and it shall not be implied the Government is committed to providing any solicitation or award following this notice. The Government will not pay for any information received in response to this request, nor will the Government compensate a respondent for any costs incurred in developing the information provided. Please note that due to the degradation properties of the requested radioisotopes any potential awardee must comply with the delivery requirements contained in the attached statement of work and provide proof that the calibrated date and time constraints can be met. Due to radiological properties and hazardous nature of requested products, any potential awardee must hold all applicable licensing and management systems as outlined in the draft SOW. If you can provide, please answer the following questions: Vendor Name: Vendor POC: Vendor SAM ID #: Vendor business size status (SDVOSB, 8(a), small/large business): Estimated delivery/lead time: Manufacturer of the item(s): a) Name: b) Place of manufacture end product: c) Size status: Provide a list of Authorized distributors (if applicable): GSA/FSS Schedule contract # (if applicable): Y/N _____ Does not exceed 1,300 employees; (NAICS 325412 - must be verifiable thru the System for Award Management). If yes, how many employees? _____ Y/N _____ Is primarily engaged in the retail or wholesale trade and normally sells the type of item being supplied; Y/N _____ Takes ownership or possession of the item(s) with its personnel, equipment or facilities in a manner consistent with industry practice (identify how this occurs); **drop shipping is an acceptable way to take possession** and Y/N _____ Will supply the end item of a small business manufacturer, processor or producer made in the United States, or obtains a waiver of such requirement pursuant to paragraph (b)(5) CFR 121.406. NOTE: If you company is a distributor, of requested products, from a vendor other than yourself please provide a copy of the Authorized Distributor letter or Letter of Authorization (LOA) from that manufacturer. Response Instructions: Do not provide more than 8 pages, including cover letter page. Submit your response via email to mark.holland@va.gov Submit your response NLT 10:00 (MST) on Thursday, November 12, 2026; Mark your response as Proprietary Information if the information is considered business sensitive. VA has identified the appropriate North American Industry Classification System (NAICS) Code as 325412 (Pharmaceutical Preparation Manufacturing) with a Small Business size of 1,300 Employees. (End of Sources Sought) | - | Market Research | 11/12/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Furoscix ReadyFlow – Diuretics – NA b. Gwyn Lo – Contraceptive Agents – Miscellaneous c. Jideytro – Lung Cancer – NA d. Omlyclo – Atopy – NA e. RizaFilm – Migraine Agents – NA f. Zenbexus – Multiple Myeloma – NA The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9403. Pre-Quotation Teleconference is on September 9, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 09/24/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 08/27/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 drug classes/subclasses will be reviewed: a. Atopy - Topical Agents Anzupgo Eucrisa Opzelura Vtama Zoryve b. Lung Cancer - METEX14 Tabrecta Tepmetko The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9401. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. | - | Solicitation | 10/01/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following August 2026 newly approved drugs will be reviewed: a. Atoncy – ADHD Agents – Subclass: Non-stimulants b. Baxfendy – Diuretics – Subclass: Mineralocorticoid Receptor Antagonists c. Duloxetine - Antidepressants And Non-opioid Pain Syndrome Agents – Subclass: SNRI d. Filkri – White Blood Cell Stimulants – Subclass: Filgrastims (Only ADP eligible due to non-TAA compliance) e. Hepcludex – Hepatitis D Agent – Subclass: NA f. Lynavoy – Gastrointestinal-2 Agents – Subclass: NA g. Veppanu - Breast Cancer Agents – Subclass: Estrogen Receptor Antagonist h. Xocova – Antivirals – Subclass: FDA Approved COVID Therapeutics i. Xtoro - Antibiotics – Subclass: Quinolones The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9304. Pre-quotation teleconference is on July 15, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POCs in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 07/27/2026 |
Additional Details
Solicitation Number
36C25926Q0144
Archive Date
Feb 28, 2026
Office Address
Greenwood Village, CO, 80111